DAPT vs. Monotherapy: The Dilemma Remains After Surgery

Patients who undergo myocardial revascularization surgery and are discharged on dual antiplatelet therapy (DAPT)—aspirin plus clopidogrel—have a lower risk of major cardiovascular and cerebral events than patients on aspirin monotherapy.

doble antiagregación plaquetaria

Furthermore, the risk of bleeding is not increased for those receiving DAPT.

This information comes from a registry of over 18,000 patients recently published in the Journal of the American Heart Association (JAHA).

This contemporary registry included all patients who underwent isolated myocardial revascularization surgery between 2013 and 2017. Of all patients, 60.1% were discharged on DAPT—clopidogrel plus aspirin—, while the rest received aspirin monotherapy.

Multiple adjustments were made to avoid confounding variables between DAPT indication and other variables that could affect the results.

Patients who received DAPT had a lower incidence of the composite endpoint (all-cause mortality, myocardial infarction, stroke, or repeat revascularization) at 6 months compared with those who received aspirin monotherapy (2.9% vs. 4.2%; hazard ratio [HR]: 0.65; 95% confidence interval [CI]: 0.55 to 0.77; p < 0,001).

This difference was still significant when considering each separate variable, namely, all-cause mortality (HR: 0.61; 95% CI: 0.41 to 0.90), infarction (HR: 0.55; 95% CI: 0.40 to 0.74), and stroke (HR: 0.58; 95% CI: 0.46 to 0.74).


Read also: Primary COVID-19 Infection Protects Against Potential Reinfection?


The incidence of major bleeding was similar between DAPT and aspirin monotherapy groups. No difference was observed when analyzing multiple risk subgroups.

Conclusion

Patients who undergo myocardial revascularization surgery find benefit in 6 months of DAPT with aspirin plus clopidogrel compared with those who receive aspirin monotherapy. This strategy translated into a significant reduction in major cardiovascular and cerebral events, and it did not have a negative effect related to bleeding.

JAHA-120-020413

Original Title: Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery.

Reference: Jianyu Qu et al. J Am Heart Assoc. 2021 Jun;10(11):e020413. doi: 10.1161/JAHA.120.020413.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...